• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Analyst Verdict: Lazard In The Eyes Of 4 Experts

    6/21/24 12:01:28 PM ET
    $LAZ
    Investment Managers
    Finance
    Get the next $LAZ alert in real time by email

    In the preceding three months, 4 analysts have released ratings for Lazard (NYSE:LAZ), presenting a wide array of perspectives from bullish to bearish.

    The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 3 1 0 0
    Last 30D 0 1 0 0 0
    1M Ago 0 0 0 0 0
    2M Ago 0 1 0 0 0
    3M Ago 0 1 1 0 0

    Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $51.25, along with a high estimate of $58.00 and a low estimate of $44.00. This upward trend is apparent, with the current average reflecting a 1.14% increase from the previous average price target of $50.67.

    price target chart

    Breaking Down Analyst Ratings: A Detailed Examination

    In examining recent analyst actions, we gain insights into how financial experts perceive Lazard. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Ryan Kenny Morgan Stanley Lowers Overweight $54.00 $58.00
    Aidan Hall Keefe, Bruyette & Woods Lowers Outperform $49.00 $51.00
    Ryan Kenny Morgan Stanley Maintains Overweight $58.00 -
    Brennan Hawken UBS Raises Neutral $44.00 $43.00

    Key Insights:

    • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lazard. This insight gives a snapshot of analysts' perspectives on the current state of the company.
    • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lazard compared to the broader market.
    • Price Targets: Gaining insights, analysts provide estimates for the future value of Lazard's stock. This comparison reveals trends in analysts' expectations over time.

    For valuable insights into Lazard's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

    Stay up to date on Lazard analyst ratings.

    About Lazard

    Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.

    A Deep Dive into Lazard's Financials

    Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

    Revenue Growth: Lazard displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 40.91%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.

    Net Margin: Lazard's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 4.45%, the company may face hurdles in effective cost management.

    Return on Equity (ROE): Lazard's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.45% ROE, the company effectively utilizes shareholder equity capital.

    Return on Assets (ROA): Lazard's ROA stands out, surpassing industry averages. With an impressive ROA of 0.75%, the company demonstrates effective utilization of assets and strong financial performance.

    Debt Management: Lazard's debt-to-equity ratio surpasses industry norms, standing at 5.9. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

    The Core of Analyst Ratings: What Every Investor Should Know

    Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

    Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $LAZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAZ

    DatePrice TargetRatingAnalyst
    1/26/2026$65.00Buy
    BofA Securities
    12/11/2025$54.00Neutral
    UBS
    10/3/2025$56.00Market Perform
    BMO Capital Markets
    8/25/2025$65.00Mkt Perform → Outperform
    Keefe Bruyette
    4/7/2025$56.00 → $33.00Equal-Weight → Underweight
    Morgan Stanley
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    12/20/2024$65.00 → $57.00Outperform → Mkt Perform
    Keefe Bruyette
    12/9/2024$60.00 → $63.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $LAZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Lazard with a new price target

    BofA Securities initiated coverage of Lazard with a rating of Buy and set a new price target of $65.00

    1/26/26 10:01:23 AM ET
    $LAZ
    Investment Managers
    Finance

    UBS resumed coverage on Lazard with a new price target

    UBS resumed coverage of Lazard with a rating of Neutral and set a new price target of $54.00

    12/11/25 9:10:59 AM ET
    $LAZ
    Investment Managers
    Finance

    BMO Capital Markets initiated coverage on Lazard with a new price target

    BMO Capital Markets initiated coverage of Lazard with a rating of Market Perform and set a new price target of $56.00

    10/3/25 8:41:45 AM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in January

    NEW YORK, Feb. 23, 2026 /PRNewswire/ -- Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.15340 per share on the Fund's outstanding common stock. The distribution is payable on March 23, 2026, to shareholders of record on March 10, 2026. The ex-dividend date is March 10, 2026. The Fund will pay a previously declared distribution today, February 23, 2026. The following table sets forth the estimated amounts of th

    2/23/26 5:07:00 PM ET
    $LAZ
    $LGI
    Investment Managers
    Finance

    LAZARD EXPANDS ITS HEALTHCARE SERVICES TEAM WITH ADDITION OF JOHN KOSKI AND ROBERT LOWE

    NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE:LAZ) today announced that John Koski and Rob Lowe joined the firm in New York as Managing Directors in the Healthcare Group, advising on transactions across the healthcare services sector. These appointments underscore Lazard's continued investment in its Healthcare Group and focus on providing thoughtful, high-quality strategic advice to executives, boards, and investors across the healthcare sector. This announcement also reflects the ongoing momentum behind Lazard's long-term growth strategy, as exceptional bankers are increasingly drawn to the firm's entrepreneurial culture, renowned brand, and global platform. 

    2/18/26 7:30:00 AM ET
    $LAZ
    Investment Managers
    Finance

    LAZARD REPORTS JANUARY 2026 ASSETS UNDER MANAGEMENT

    NEW YORK, Feb. 10, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE:LAZ) reported today that its preliminary assets under management ("AUM") as of January 31, 2026 totaled approximately $267.0 billion. The month's AUM included market appreciation of $7.6 billion, net inflows of $2.9 billion and FX appreciation of $2.1 billion. LAZARD, INC. ASSETS UNDER MANAGEMENT ("AUM") (unaudited) ($ in millions) As of:  January 31,  December 31,  20261 2025 Equity $195,775 $184,472 Fixed Income 35,758 35,065 Multi Asset 25,267 24,783 Alternatives 10,153 9,980 Total AUM $266,953 $254,300 (1) Preli

    2/10/26 6:45:00 AM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    SEC Filings

    View All

    SEC Form 10-K filed by Lazard Inc.

    10-K - Lazard, Inc. (0001311370) (Filer)

    2/23/26 4:33:41 PM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Lazard, Inc. (0001311370) (Filer)

    2/2/26 5:00:04 PM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lazard, Inc. (0001311370) (Filer)

    1/29/26 6:32:17 AM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Gathy Michael

    4 - Lazard, Inc. (0001311370) (Issuer)

    2/23/26 5:16:02 PM ET
    $LAZ
    Investment Managers
    Finance

    SEC Form 4 filed by Chief Operating Officer Soto Alexandra

    4 - Lazard, Inc. (0001311370) (Issuer)

    2/23/26 5:16:08 PM ET
    $LAZ
    Investment Managers
    Finance

    SEC Form 4 filed by Chief Financial Officer Farr Tracy

    4 - Lazard, Inc. (0001311370) (Issuer)

    2/23/26 5:15:50 PM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    Leadership Updates

    Live Leadership Updates

    View All

    LAZARD EXPANDS ITS HEALTHCARE SERVICES TEAM WITH ADDITION OF JOHN KOSKI AND ROBERT LOWE

    NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE:LAZ) today announced that John Koski and Rob Lowe joined the firm in New York as Managing Directors in the Healthcare Group, advising on transactions across the healthcare services sector. These appointments underscore Lazard's continued investment in its Healthcare Group and focus on providing thoughtful, high-quality strategic advice to executives, boards, and investors across the healthcare sector. This announcement also reflects the ongoing momentum behind Lazard's long-term growth strategy, as exceptional bankers are increasingly drawn to the firm's entrepreneurial culture, renowned brand, and global platform. 

    2/18/26 7:30:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Asset Management Appoints Eric Van Nostrand as Chief Investment Officer

    CIO role established to reinforce investment excellence, deepen global investment connectivity and further enhance Lazard's research-driven platform Lazard Asset Management ("LAM") today announced that Eric Van Nostrand has been appointed Chief Investment Officer (CIO), a newly created role established to strengthen the cohesion, discipline, and effectiveness of LAM's global investment platform. As CIO, he will be responsible for investment oversight and for advancing the processes that support consistent, long‑term outcomes for clients. In this role, Mr. Van Nostrand will partner closely with LAM's investment leaders to strengthen portfolio construction standards, deepen research rigor

    1/6/26 8:30:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Bolsters Global Industrials Practice by Adding Three New Managing Directors

    Bill Young Joins the Firm as a Managing Director and Head of Diversified Industrials Jean Greene Rejoins the Firm as a Managing Director Paolo Battaglia to Join the Firm as a Managing Director Lazard, Inc. (NYSE:LAZ), the preeminent global financial advisory and asset management firm, announced today the appointments of Bill Young, Jean Greene, and Paolo Battaglia as Managing Directors in the firm's Global Industrials Group, all based in New York. These appointments further strengthen Lazard's market-leading global Industrials franchise, which advises clients across diversified industrials, building products, chemicals, paper & packaging, transportation & logistics, industrial technology,

    11/25/25 7:45:00 AM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    Financials

    Live finance-specific insights

    View All

    Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in January

    NEW YORK, Feb. 23, 2026 /PRNewswire/ -- Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.15340 per share on the Fund's outstanding common stock. The distribution is payable on March 23, 2026, to shareholders of record on March 10, 2026. The ex-dividend date is March 10, 2026. The Fund will pay a previously declared distribution today, February 23, 2026. The following table sets forth the estimated amounts of th

    2/23/26 5:07:00 PM ET
    $LAZ
    $LGI
    Investment Managers
    Finance

    Lazard Reports Fourth Quarter and Full Year 2025 Results

    Record full-year Financial Advisory adjusted net revenue of $1.8 billionRecord full-year Asset Management inflows and total AUM up 12% year-over-yearFinancial Advisory ahead of 2030 targets, with revenue per MD of $8.9 million1 and 21 Managing Directors hired during 2025NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE:LAZ) today reported net revenue of $907 million and adjusted net revenue2 of $892 million for the quarter ended December 31, 2025. For the full year of 2025, Lazard reported net revenue of $3,099 million and adjusted net revenue2 of $3,030 million. On a

    1/29/26 6:30:00 AM ET
    $LAZ
    Investment Managers
    Finance

    Lazard Declares Quarterly Dividend of $0.50 per Share

    NEW YORK, Jan. 28, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE:LAZ) today announced that its Board of Directors has voted to declare a quarterly dividend of $0.50 per share on its outstanding common stock. The dividend is payable on February 20, 2026, to stockholders of record on February 9, 2026. About Lazard Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restr

    1/28/26 4:15:00 PM ET
    $LAZ
    Investment Managers
    Finance

    $LAZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lazard Inc.

    SC 13G - Lazard, Inc. (0001311370) (Subject)

    11/8/24 2:17:07 PM ET
    $LAZ
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by Lazard LTD. Lazard LTD. (Amendment)

    SC 13G/A - Lazard, Inc. (0001311370) (Subject)

    2/14/24 9:41:26 AM ET
    $LAZ
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by Lazard LTD. Lazard LTD. (Amendment)

    SC 13G/A - Lazard, Inc. (0001311370) (Subject)

    2/9/24 9:16:05 AM ET
    $LAZ
    Investment Managers
    Finance